Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder
Frontiers in Psychiatry – June 11, 2024
Source: OpenAlex
Summary
A compelling new avenue in psychiatry explores psilocybin, a powerful hallucinogen, for treatment-resistant conditions like major depressive disorder and obsessive compulsive disorder. Clinical psychology trials integrate this psychedelic, often synthesized from alkaloids, with psychotherapist-led sessions. Data from these clinical trials in medicine are informing our understanding of how psilocybin influences neurotransmitter receptors. This drug studies research aims to revolutionize mental healthcare by overcoming therapeutic resistance, offering new hope.
Abstract
Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conducted to find effective alternatives to traditional therapies. One of these alternatives is psilocybin, a psychedelic substance that has been tested in clinical trials as an adjunct to psychotherapy. These studies focus on patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD) and substance use disorder (SUD), particularly alcohol and nicotine dependence. This article looks at the current understanding of psilocybin, including data from clinical trials conducted, psilocybin’s mechanism of action, its safety and the level of risk associated with it.